IS4706A - Lyfjasamsetningar - Google Patents

Lyfjasamsetningar

Info

Publication number: IS4706A
Authority: IS; Iceland
Prior art keywords: pharmaceutical compositions; pharmaceutical; compositions
Prior art date: 1995-11-21

Application number

IS4706A

Other languages

English (en)

Inventor

James Macrae Ross

Sarah Smith Janet

Original Assignee

Pfizer Research And Development Company, N.V/S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-21

Filing date

1998-03-31

Publication date

1998-03-31

1998-03-31 Application filed by Pfizer Research And Development Company, N.V/S.A. filed Critical Pfizer Research And Development Company, N.V/S.A.

1998-03-31 Publication of IS4706A publication Critical patent/IS4706A/is

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS4706A 1995-11-21 1998-03-31 Lyfjasamsetningar IS4706A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9523752.5A GB9523752D0 (en)	1995-11-21	1995-11-21	Pharmaceutical formulations
PCT/EP1996/005020 WO1997018814A1 (en)	1995-11-21	1996-11-11	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
IS4706A true IS4706A (is)	1998-03-31

Family

ID=10784188

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS4706A IS4706A (is)	1995-11-21	1998-03-31	Lyfjasamsetningar

Country Status (29)

Country	Link
EP (1)	EP0862437A1 (is)
JP (1)	JPH10513481A (is)
KR (1)	KR19990071505A (is)
CN (1)	CN1215993A (is)
AP (1)	AP718A (is)
AR (1)	AR004335A1 (is)
AU (1)	AU709560B2 (is)
BG (1)	BG102438A (is)
BR (1)	BR9611626A (is)
CA (1)	CA2232715A1 (is)
CO (1)	CO4480020A1 (is)
CZ (1)	CZ155498A3 (is)
GB (1)	GB9523752D0 (is)
HR (1)	HRP960554A2 (is)
HU (1)	HUP9903734A3 (is)
IS (1)	IS4706A (is)
MA (1)	MA26410A1 (is)
MX (1)	MX9804008A (is)
NO (1)	NO982302L (is)
NZ (1)	NZ322053A (is)
OA (1)	OA10687A (is)
PE (1)	PE22898A1 (is)
PL (1)	PL326981A1 (is)
SK (1)	SK63098A3 (is)
TN (1)	TNSN96141A1 (is)
TR (1)	TR199800902T2 (is)
WO (1)	WO1997018814A1 (is)
YU (1)	YU62096A (is)
ZA (1)	ZA969722B (is)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5945125A (en) *	1995-02-28	1999-08-31	Temple University	Controlled release tablet
NZ504487A (en) *	1997-12-16	2002-11-26	Pfizer Prod Inc	Combination of alpha-adrenergic antagonists and cGMP elevators for the treatment of impotence
EP2332522A3 (en)	1998-03-19	2011-12-07	Bristol-Myers Squibb Company	Biphasic controlled release delivery system for high solubility pharmaceuticals and method
GT199900061A (es) *	1998-05-15	2000-10-14	Pfizer	Formulaciones farmaceuticas.
EP0987020A1 (en) *	1998-09-04	2000-03-22	Pharma Pass LLC	Metoprolol composition and processes for manufacturing the same
EP0974343B1 (en) *	1998-07-22	2004-09-29	Pharma Pass II LLC	Process for manufacturing a solid metoprolol composition
CO5140079A1 (es) *	1998-10-14	2002-03-22	Novartis Ag	Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
UA67802C2 (uk)	1998-10-23	2004-07-15	Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А.	Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US20030059467A1 (en) *	2001-09-14	2003-03-27	Pawan Seth	Pharmaceutical composition comprising doxasozin
TWI312285B (en)	2001-10-25	2009-07-21	Depomed Inc	Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en)	2001-10-25	2009-11-03	Depomed, Inc.	Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en)	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
US8329217B2 (en)	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1680078A2 (en) *	2003-10-17	2006-07-19	Ranbaxy Laboratories, Ltd.	Oral matrix formulations of doxazosin
US20050255157A1 (en) *	2004-05-11	2005-11-17	Glenmark Pharmaceuticals Limited	Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (ko) *	2004-05-28	2006-04-27	한미약품 주식회사	니아신의 경구투여용 서방성 조성물
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR100679111B1 (ko) *	2004-11-20	2007-02-07	대우약품공업주식회사	독사조신을 포함하는 서방성 정제
JP2009504796A (ja) *	2005-08-22	2009-02-05	ノバルティスアクチエンゲゼルシャフト	ｐＨ依存性薬剤化合物、ｐＨ調整剤および遅延剤を含む医薬組成物
US20090176882A1 (en)	2008-12-09	2009-07-09	Depomed, Inc.	Gastric retentive gabapentin dosage forms and methods for using same
AU2007242984B2 (en)	2006-04-26	2012-11-08	Supernus Pharmaceuticals Inc.	Controlled released preparations of oxcarbazepine having sigmoidal release profile
AU2007247190A1 (en)	2006-05-04	2007-11-15	Boehringer Ingelheim International Gmbh	Polymorphs
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN100396282C (zh) *	2006-07-25	2008-06-25	山东省医药工业研究所	甲磺酸多沙唑嗪缓释胶囊及制备方法
SA07280459B1 (ar)	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8377453B2 (en)	2008-03-11	2013-02-19	Depomed, Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en)	2008-03-11	2013-02-12	Depomed, Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
TWI478712B (zh)	2008-09-30	2015-04-01	Astellas Pharma Inc	釋控性醫藥組成物
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (ko) *	2008-12-17	2010-12-24	동아제약주식회사	유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
EP2395983B1 (en)	2009-02-13	2020-04-08	Boehringer Ingelheim International GmbH	Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
US9901551B2 (en)	2009-04-20	2018-02-27	Ambra Bioscience Llc	Chemosensory receptor ligand-based therapies
US8828953B2 (en)	2009-04-20	2014-09-09	NaZura BioHealth, Inc.	Chemosensory receptor ligand-based therapies
BRPI1013856A2 (pt)	2009-04-20	2016-04-05	Elcelyx Therapeutics Inc	terapias à base de ligantes de receptores quimiossensíveis
US9457029B2 (en)	2009-11-27	2016-10-04	Boehringer Ingelheim International Gmbh	Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9198861B2 (en)	2009-12-22	2015-12-01	Mallinckrodt Llc	Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) *	2009-12-22	2011-06-23	Mallinkckrodt Inc.	Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
ES2935300T3 (es)	2010-05-05	2023-03-03	Boehringer Ingelheim Int	Combiterapia
RU2016125229A (ru)	2010-07-09	2018-12-04	БиЭйчВи ФАРМА, ИНК.	Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
AU2011317140A1 (en)	2010-10-19	2013-05-30	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
LT2661266T (lt)	2011-01-07	2020-12-10	Anji Pharma (Us) Llc	Gydimo būdai chemosensorinio receptoriaus ligando pagrindu
CN102058555A (zh) *	2011-01-13	2011-05-18	北京汇诚瑞祥医药技术有限公司	一种多沙唑嗪控释片
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
CN102188431A (zh) *	2011-05-09	2011-09-21	浙江九旭药业有限公司	甲磺酸多沙唑嗪缓释片及其制备方法
US8741885B1 (en)	2011-05-17	2014-06-03	Mallinckrodt Llc	Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en)	2011-05-17	2015-06-09	Mallinckrodt Llc	Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en)	2011-05-17	2014-10-14	Mallinckrodt Llc	Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US20130143867A1 (en)	2011-12-02	2013-06-06	Sychroneuron Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013158928A2 (en)	2012-04-18	2013-10-24	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
WO2013171167A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3878445A3 (en)	2013-06-05	2021-10-27	Synchroneuron Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3110449B1 (en)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medical use of a dpp-4 inhibitor
CN105616378A (zh) *	2014-10-31	2016-06-01	康普药业股份有限公司	一种氟康唑胶囊及其制备方法
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin
US12097189B1 (en)	2024-02-09	2024-09-24	Astellas Pharma Inc.	Pharmaceutical composition for modified release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1198386B (it) *	1982-07-06	1988-12-21	Lepetit Spa	Un prodotto a rilascio protratto contenente il suloctidile
US4765989A (en) *	1983-05-11	1988-08-23	Alza Corporation	Osmotic device for administering certain drugs
US4837111A (en) *	1988-03-21	1989-06-06	Alza Corporation	Dosage form for dispensing drug for human therapy
IL92966A (en) *	1989-01-12	1995-07-31	Pfizer	Hydrogel-operated release devices
NZ239033A (en) *	1990-07-23	1994-04-27	Alza Corp	Semipermeable capsule with a hole containing a nicotine salt which reacts with water to release nicotine base

1995
- 1995-11-21 GB GBGB9523752.5A patent/GB9523752D0/en active Pending
1996
- 1996-11-11 WO PCT/EP1996/005020 patent/WO1997018814A1/en not_active Application Discontinuation
- 1996-11-11 HU HU9903734A patent/HUP9903734A3/hu unknown
- 1996-11-11 CN CN96198486A patent/CN1215993A/zh active Pending
- 1996-11-11 KR KR1019980703777A patent/KR19990071505A/ko not_active Application Discontinuation
- 1996-11-11 AU AU75721/96A patent/AU709560B2/en not_active Ceased
- 1996-11-11 NZ NZ322053A patent/NZ322053A/xx unknown
- 1996-11-11 SK SK630-98A patent/SK63098A3/sk unknown
- 1996-11-11 JP JP9519364A patent/JPH10513481A/ja active Pending
- 1996-11-11 TR TR1998/00902T patent/TR199800902T2/xx unknown
- 1996-11-11 BR BR9611626A patent/BR9611626A/pt not_active Application Discontinuation
- 1996-11-11 CZ CZ981554A patent/CZ155498A3/cs unknown
- 1996-11-11 EP EP96938215A patent/EP0862437A1/en not_active Withdrawn
- 1996-11-11 PL PL96326981A patent/PL326981A1/xx unknown
- 1996-11-11 CA CA002232715A patent/CA2232715A1/en not_active Abandoned
- 1996-11-20 ZA ZA9609722A patent/ZA969722B/xx unknown
- 1996-11-20 PE PE1996000831A patent/PE22898A1/es not_active Application Discontinuation
- 1996-11-20 TN TNTNSN96141A patent/TNSN96141A1/fr unknown
- 1996-11-20 YU YU62096A patent/YU62096A/sh unknown
- 1996-11-20 AR ARP960105252A patent/AR004335A1/es unknown
- 1996-11-20 MA MA24397A patent/MA26410A1/fr unknown
- 1996-11-21 CO CO96061449A patent/CO4480020A1/es unknown
- 1996-11-21 HR HR9523752.5A patent/HRP960554A2/hr not_active Application Discontinuation
- 1996-11-21 AP APAP/P/1996/000883A patent/AP718A/en active
1998
- 1998-03-31 IS IS4706A patent/IS4706A/is unknown
- 1998-05-08 BG BG102438A patent/BG102438A/xx unknown
- 1998-05-19 OA OA9800058A patent/OA10687A/en unknown
- 1998-05-20 MX MX9804008A patent/MX9804008A/es unknown
- 1998-05-20 NO NO982302A patent/NO982302L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO1997018814A1 (en)	1997-05-29
EP0862437A1 (en)	1998-09-09
MX9804008A (es)	1998-09-30
KR19990071505A (ko)	1999-09-27
TNSN96141A1 (fr)	2005-03-15
AP9600883A0 (en)	1997-01-31
ZA969722B (en)	1998-05-20
PL326981A1 (en)	1998-11-09
AU7572196A (en)	1997-06-11
BR9611626A (pt)	1999-06-01
HUP9903734A3 (en)	2000-04-28
OA10687A (en)	2002-11-27
YU62096A (sh)	1999-03-04
SK63098A3 (en)	1999-05-07
MA26410A1 (fr)	2004-12-20
NO982302L (no)	1998-07-17
PE22898A1 (es)	1998-05-07
CO4480020A1 (es)	1997-07-09
CA2232715A1 (en)	1997-05-29
BG102438A (en)	1999-01-29
HRP960554A2 (en)	1998-02-28
NO982302D0 (no)	1998-05-20
GB9523752D0 (en)	1996-01-24
AR004335A1 (es)	1998-11-04
HUP9903734A2 (hu)	2000-03-28
CN1215993A (zh)	1999-05-05
CZ155498A3 (cs)	1999-03-17
AU709560B2 (en)	1999-09-02
JPH10513481A (ja)	1998-12-22
AP718A (en)	1999-01-06
NZ322053A (en)	1999-11-29
TR199800902T2 (xx)	1998-09-21

Publication	Publication Date	Title
IS4706A (is)	1998-03-31	Lyfjasamsetningar
NO962606D0 (no)	1996-06-19	Farmasöytisk sammensetning
CY2005007I1 (el)	2009-11-04	Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
FI974241A0 (fi)	1997-11-14	BPM-15 -koostumukset
DK0747050T3 (da)	2003-12-15	Farmaceutiske sammensætninger indeholdende irbesartan
ID18352A (id)	1998-04-02	Komposisi-komposisi farmasi
BR9610396A (pt)	1999-07-06	Formulação farmacêutica
NO981568D0 (no)	1998-04-06	Randtennings-tennsatssammensetninger
DE69617029D1 (de)	2001-12-20	Organoton-zusammensetzungen
BR9610214A (pt)	1999-06-15	Compostos farmacéuticos
DE69614407D1 (de)	2001-09-13	Pharmazeutische zusammensetzungen
LV11727A (lv)	1997-04-20	Farmaceitiska kompozicija
FI973229A0 (fi)	1997-08-05	Uusi farmaseuttinen koostumus
BR9507768A (pt)	1997-09-02	Composição farmacêutica
PT969815E (pt)	2005-07-29	Composicoes farmaceuticas
PT941100E (pt)	2003-10-31	Composicoes farmaceuticas
EE200000330A (et)	2001-08-15	Farmatseutilised kompositsioonid
FI973280A0 (fi)	1997-08-08	Farmaseuttinen koostumus
ITMI942166A0 (it)	1994-10-21	Composizioni farmaceutiche miorilassanti
DE69603228D1 (de)	1999-08-19	Aluminoxanate-Zusammensetzungen
FI973230A (fi)	1997-08-05	Uusi farmaseuttinen formulaatio
ATE206150T1 (de)	2001-10-15	Farbstoffstabilisierte zusammensetzungen
EE9800168A (et)	1998-12-15	Tahked kompositsioonid
NO965448D0 (no)	1996-12-18	Farmasöytiske forbindelser
BR9605777A (pt)	1998-08-25	Composição farmacêutica